Franklin Biotechnology Discovery FundFRBRX
Type
Mutual fund
Peer group
Global equity
Net assets
$1.0B
Expense ratio
0.67%
1-year return
+65.6%
3 years, a year
+23.7%
5 years, a year
+8.5%
Holdings
113
What it aims to do.
Capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| Jazz Pharmaceuticals plc | 5.55% |
| AMGN Amgen, Inc. | 4.75% |
| GILD Gilead Sciences, Inc. | 4.66% |
| REGN Regeneron Pharmaceuticals, Inc. | 4.17% |
| VRTX Vertex Pharmaceuticals, Inc. | 4.02% |
| ARGX Argenx SE | 3.69% |
| Franklin Institutional U.S. Government Money Market Fund | 3.05% |
| Franklin Institutional U.S. Government Money Market Fund | 2.96% |
| Ascendis Pharma A/S | 2.87% |
| INSM Insmed, Inc. | 2.82% |
More on FRBRX.
- FRBRX overview
- FRBRX holdings
- FRBRX risk
- FRBRX costs
- FRBRX money in and out
- FRBRX share classes
- Compare FRBRX with other funds
Returns after fees, from the fund's SEC filings up to Apr 2026. Past returns are not a promise. Not financial advice.